TEL AVIV, Israel & GLASGOW, Scotland--(BUSINESS WIRE)--Nucleai, a leader in AI-powered spatial biology for precision medicine, and the University of Glasgow, a global leader in spatial proteomics and transcriptomics research, today...

Proscia: Expanding Proscia’s precision medicine AI pipeline will help to optimize clinical trials and improve treatment decisions PHILADELPHIA and CHICAGO – JUNE 25, 2024 – Proscia®, a global leader in AI-enabled pathology solutions...

CHICAGO--(BUSINESS WIRE)--Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration...

The Extension Funds Nucleai to Advance Its First-in-Class Spatial AI Biomarker in Active Clinical Enrollment Investment Expands Deployments of AI-Powered Spatial Biomarker Technology, Strengthening Companion Diagnostics for ADCs,...

TEL AVIV, Israel--(BUSINESS WIRE)--Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning...

Combining the power of spatial biology and AI, Propath and Nucleai push the boundaries of pathology tissue analytics to develop a novel, high multiplexed immunofluorescence (IF) panel and associated AI-powered algorithm for biomarker...